0000899243-20-015413.txt : 20200605
0000899243-20-015413.hdr.sgml : 20200605
20200605160603
ACCESSION NUMBER: 0000899243-20-015413
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200603
FILED AS OF DATE: 20200605
DATE AS OF CHANGE: 20200605
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fox Jonathan C
CENTRAL INDEX KEY: 0001655016
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38533
FILM NUMBER: 20946160
MAIL ADDRESS:
STREET 1: C/O MYOKARDIA, INC.
STREET 2: 333 ALLERTON AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Eidos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001731831
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463733671
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: 650-391-9740
MAIL ADDRESS:
STREET 1: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-03
0
0001731831
Eidos Therapeutics, Inc.
EIDX
0001655016
Fox Jonathan C
C/O EIDOS THERAPEUTICS, INC.
101 MONTGOMERY STREET, SUITE 2000
SAN FRANCISCO
CA
94104
0
1
0
0
See Remarks
Common Stock
2020-05-31
5
A
0
E
444
41.5735
A
3294
D
Common Stock
2020-06-01
5
G
0
E
1020
0.00
D
397605
I
See footnote
Common Stock
2020-06-02
5
G
0
E
1020
0.00
D
396585
I
See footnote
Common Stock
2020-06-03
4
S
0
5000
50.00
D
391585
I
See footnote
Shares acquired pursuant to the Issuer's 2018 Employee Stock Purchase Plan.
The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014.
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2020.
President and Chief Medical Officer
/s/ Franco Valle, as Attorney-in-Fact
2020-06-05